John W. A. Findlay

4.8k total citations · 1 hit paper
94 papers, 3.6k citations indexed

About

John W. A. Findlay is a scholar working on Molecular Biology, Astronomy and Astrophysics and Pharmacology. According to data from OpenAlex, John W. A. Findlay has authored 94 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 15 papers in Astronomy and Astrophysics and 13 papers in Pharmacology. Recurrent topics in John W. A. Findlay's work include Poisoning and overdose treatments (7 papers), Radio Astronomy Observations and Technology (7 papers) and Pharmacological Receptor Mechanisms and Effects (6 papers). John W. A. Findlay is often cited by papers focused on Poisoning and overdose treatments (7 papers), Radio Astronomy Observations and Technology (7 papers) and Pharmacological Receptor Mechanisms and Effects (6 papers). John W. A. Findlay collaborates with scholars based in United States, United Kingdom and New Zealand. John W. A. Findlay's co-authors include Richard M. Welch, Iain J. McGilveray, Rabindra Patnaik, Mark L. Powell, James D. Hulse, Alfred Tonelli, C.T. Viswanathan, Avraham Yacobi, Howard Hill and Kamal K. Midha and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of the American College of Cardiology.

In The Last Decade

John W. A. Findlay

90 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bioanalytical Method Validation—A Revisit with a Decade of Progress

2000 1.4k citations Vinod P. Shah, Kamal K. Midha et al. Pharmaceutical Research profile →

Peers

Countries citing papers authored by John W. A. Findlay

Since Specialization

Citations

This map shows the geographic impact of John W. A. Findlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. A. Findlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. A. Findlay more than expected).

Fields of papers citing papers by John W. A. Findlay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. A. Findlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. A. Findlay. The network helps show where John W. A. Findlay may publish in the future.

Co-authorship network of co-authors of John W. A. Findlay

This figure shows the co-authorship network connecting the top 25 collaborators of John W. A. Findlay. A scholar is included among the top collaborators of John W. A. Findlay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. A. Findlay. John W. A. Findlay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS 2011 ·Journal of Hepatology ·Uri Lopatin, Grushenka H.I. Wolfgang, (unknown), (unknown), (unknown), Gregory E. Chittick, Christian Frey, John W. A. Findlay, (unknown), Brian P. Kearney, Chris Barnes, John McHutchinson, Kenneth Hirsch	6
2	Ligand-binding assays : development, validation, and implementation in the drug development arena 2010 ·Wiley eBooks ·Masood N. Khan, John W. A. Findlay	25
3	Some important considerations for validation of ligand-binding assays 2008 ·Journal of Chromatography B ·John W. A. Findlay	15
4	Appropriate calibration curve fitting in ligand binding assays 2007 ·The AAPS Journal ·John W. A. Findlay, (unknown)	294
5	Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice 2003 ·Xenobiotica ·(unknown), (unknown), John W. A. Findlay, (unknown), V C Knick, (unknown), Luis Molina	17
6	Bioanalytical Method Validation—A Revisit with a Decade of Progress breakdown → 2000 ·Pharmaceutical Research ·Vinod P. Shah, Kamal K. Midha, John W. A. Findlay, Howard Hill, James D. Hulse, Iain J. McGilveray, Gordon McKay, (unknown), Rabindra Patnaik, Mark L. Powell, Alfred Tonelli, C.T. Viswanathan, Avraham Yacobi	1353
7	Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey 2000 ·Xenobiotica ·S. K. Paulson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mei‐Ping Chang, (unknown), John W. A. Findlay, (unknown), (unknown), Alan P. Breau, Jeremy D. Hribar, (unknown)	22
8	Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment 1991 ·Journal of the American College of Cardiology ·Nancy M. Allen LaPointe, (unknown), (unknown), John W. A. Findlay	2
9	Treatment of Digoxin Intoxication in a Renal Failure Patient with Digoxin-Specific Antibody Fragments and Plasmapheresis 1990 ·American Journal of Nephrology ·(unknown), (unknown), John W. A. Findlay, Jeffrey Sailstad	19
10	Survival Associated with Renovascular Disease in Glasgow and Newcastle: A Collaborative Study 1990 ·Scottish Medical Journal ·Chris Isles, John Main, John B. O’Connell, Ivan Brown, John W. A. Findlay, Robert Stewart, Robert W. Wilkinson	50
11	The pharmacokinetics of digoxin immune fab total digoxin and free digoxin in patients with renal impairment 1989 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Robert D. Colucci, (unknown), Jeffrey Kluger, Jeffrey Sailstad, John W. A. Findlay, Romnie Long	3
12	Pharmacokinetics of Acrivastine After Oral and Colonic Administration 1989 ·The Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), (unknown), John W. A. Findlay, M.F. Frosolono	10
13	Pharmacokinetics of Codeine After Single‐and Multiple‐Oral‐Dose Administration to Normal Volunteers 1987 ·The Journal of Clinical Pharmacology ·David R.P. Guay, Walid M. Awni, C E Halstenson, John W. A. Findlay, John A. Opsahl, (unknown), Evelyn Jones, Gary R. Matzke	35
14	Upgrading the 11-meter antenna of the National Radio Astronomy Observatory. 1983 ·John W. A. Findlay, J. M. Payne	2
15	Plasma Levels of a Novel Antidysrhythmic Agent, Meobentine Sulfate, in Humans as Determined by Radioimmunoassay 1982 ·Journal of Pharmaceutical Sciences ·James T. Warren, (unknown), Richard M. Welch, A. S. E. Fowle, John W. A. Findlay	6
16	Disposition and phenacetin in dog and man determined by a sensitive and specific radioimmunoassay. 1979 ·Journal of Pharmacology and Experimental Therapeutics ·John W. A. Findlay, Richard DeAngelis, Robert F. Butz, (unknown), Richard M. Welch	2
17	Specific radioimmunoassays for codeine and morphine. Metabolism of codeine to morphine in the rat. 1977 ·PubMed ·John W. A. Findlay, Robert F. Butz, Richard M. Welch	8
18	Radio telescopes 1964 ·John W. A. Findlay	5
19	The 300-Foot Radio Telescope at Green Bank 1963 ·S&T ·John W. A. Findlay	4
20	Vertical Incidence Doppler Ionogram 1961 ·Proceedings of the IRE ·John W. A. Findlay	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact